NewAmsterdam Pharma (NASDAQ:NAMS) Given Average Rating of “Buy” by Brokerages

Shares of NewAmsterdam Pharma (NASDAQ:NAMS) have earned a consensus rating of “Buy” from the seven research firms that are presently covering the firm, Marketbeat reports. Seven investment analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $33.80.

Several equities analysts have recently commented on NAMS shares. Needham & Company LLC started coverage on shares of NewAmsterdam Pharma in a report on Wednesday, August 28th. They set a “buy” rating and a $36.00 price target on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $31.00 target price on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th.

Insider Activity

In other news, CEO Michael H. Davidson acquired 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 20th. The stock was acquired at an average cost of $17.26 per share, with a total value of $86,300.00. Following the acquisition, the chief executive officer now owns 204,784 shares in the company, valued at $3,534,571.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 19.50% of the stock is currently owned by insiders.

Institutional Trading of NewAmsterdam Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Banque Cantonale Vaudoise bought a new stake in shares of NewAmsterdam Pharma in the second quarter valued at approximately $38,000. Sei Investments Co. grew its position in NewAmsterdam Pharma by 49.1% in the 2nd quarter. Sei Investments Co. now owns 24,561 shares of the company’s stock worth $472,000 after purchasing an additional 8,087 shares during the last quarter. Wolverine Asset Management LLC increased its holdings in shares of NewAmsterdam Pharma by 117.7% during the 2nd quarter. Wolverine Asset Management LLC now owns 15,524 shares of the company’s stock worth $298,000 after purchasing an additional 8,394 shares during the period. Rosalind Advisors Inc. acquired a new position in shares of NewAmsterdam Pharma during the second quarter valued at about $194,000. Finally, Yarbrough Capital LLC bought a new stake in shares of NewAmsterdam Pharma in the first quarter valued at about $567,000. Institutional investors and hedge funds own 89.89% of the company’s stock.

NewAmsterdam Pharma Price Performance

Shares of NewAmsterdam Pharma stock opened at $15.84 on Tuesday. NewAmsterdam Pharma has a 1 year low of $5.63 and a 1 year high of $26.35. The stock has a 50-day moving average price of $17.29 and a 200 day moving average price of $19.40.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.08. The company had revenue of $2.28 million for the quarter, compared to analyst estimates of $2.20 million. On average, equities analysts forecast that NewAmsterdam Pharma will post -2.06 earnings per share for the current fiscal year.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.